Mark Alvino Biography and Net Worth

Director of Abeona Therapeutics

Mr. Alvino has provided leadership and experience in the areas of financial management and business strategy as a member of the Board of Directors of multiple life sciences companies, including PainQx, a company with a patented method for objective, quantitative assessment of chronic pain, and previously serving on Abeona’s Board of Directors. He has more than 25 years of experience in the pharmaceutical and biotechnology industries through a range of disciplines including healthcare investment banking, communications, business consulting, market research and health and medical marketing communications. In his role at Hudson Square Capital, Mr. Alvino provides strategic advisory to emerging growth and turnaround biotechnology and medical technology companies. Mr. Alvino is also Founder and Chief Executive Officer of Bridge Back Foundation, focused on addressing the broad underlying issues behind the deadly opioid crisis in America. Previously, he led the Life Sciences team at broker dealer Bradley Woods & Co. Ltd. and served as Managing Director at Griffin Securities and at SCO Financial Group, LLC. Earlier in his career, he spent several years working with Wall Street brokerages including Ladenburg, Thalmann & Co. and Martin Simpson & Co. Mr. Alvino received a B.B.A in Economics and Public Policy from the George Washington University.

What is Mark Alvino's net worth?: The estimated net worth of Mark Alvino is at least $303.17 thousand as of November 13th, 2025. Alvino owns 62,252 shares of Abeona Therapeutics stock worth more than $303,167 as of December 4th. This net worth approximation does not reflect any other assets that Alvino may own. Learn More about Mark Alvino's net worth.
How do I contact Mark Alvino?: The corporate mailing address for Alvino and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Mark Alvino's contact information.
Has Mark Alvino been buying or selling shares of Abeona Therapeutics?: During the last quarter, Mark Alvino has sold $71,100.00 in shares of Abeona Therapeutics stock. Most recently, Mark Alvino sold 15,000 shares of the business's stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $4.74, for a transaction totalling $71,100.00. Following the completion of the sale, the director now directly owns 62,252 shares of the company's stock, valued at $295,074.48. Learn More on Mark Alvino's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Leila Alland (Director), Mark Alvino (Director), Michael Amoroso (CEO), Edward Carr (CAO), Faith Charles (Director), Brendan O'Malley (SVP), Vishwas Seshadri (CEO), Christine Silverstein (Director), Joseph Vazzano (CFO), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 22 times. They sold a total of 351,238 shares worth more than $2,047,717.92. The most recent insider tranaction occured on November, 13th when Director Mark Alvino sold 15,000 shares worth more than $71,100.00. Insiders at Abeona Therapeutics own 6.9% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 11/13/2025.

Mark Alvino Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/13/2025	Sell	15,000	$4.74	$71,100.00	62,252
7/9/2025	Sell	13,093	$5.86	$76,724.98	77,252
5/27/2025	Sell	2,000	$6.38	$12,760.00	90,435
5/16/2025	Sell	8,000	$5.68	$45,440.00	92,435
1/29/2025	Sell	4,000	$5.38	$21,520.00	64,334
1/21/2025	Sell	4,000	$5.10	$20,400.00	68,334
1/17/2024	Sell	7,084	$5.11	$36,199.24	62,816
6/6/2022	Sell	35,000	$0.16	$5,600.00	47,181

Mark Alvino Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $4.87

$4.69

$4.92

50 Day Range

MA: $4.99

$4.17

$5.66

2 Week Range

Now: $4.87

$3.93

$7.54

Volume

954,439 shs

Average Volume

2,466,979 shs

Market Capitalization

$263.91 million

P/E Ratio

3.96

Dividend Yield

N/A

Beta

1.12